---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-002728"
form_type: "8-K"
ticker: "USBC"
cik: "0001074828"
company_name: "USBC, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:20:31.332082+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Know Labs’ RF glucose sensor achieves 11.1% MARD in first venous-blood study

## Summary
- Overall MARD of 11.1±2.1% in test dataset; similar accuracy in normoglycemic (11.0%) and hyperglycemic (11.5%) ranges.
- First study using venous blood as reference in participants with prediabetes and Type 2 diabetes.
- Study involved 21 three-hour sessions with 75g OGTT; 520 paired values for training, 130 for test.
- Clinical trial completed (up to 100 participants, Sep 2023–Feb 2024); company plans large-scale external trials in 2024.
- Dr. Virend K. Somers of Mayo Clinic is co-investigator; results presented at ATTD conference in Florence.

## SEC filing metadata
- accession: 0001654954-24-002728
- form_type: 8-K
- ticker: USBC
- cik: 0001074828
- company_name: USBC, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1074828/000165495424002728/0001654954-24-002728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1074828/000165495424002728/knwn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-002728
- JSON: https://secwatch.observer/filing/0001654954-24-002728.json
- Plain text: https://secwatch.observer/filing/0001654954-24-002728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.